# US 2023/0417761 A1 · Detection and quantification of natalizumab

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0417761 A1
- Document ID: US20230417761A1
- Status: Published application
- Kind: A1
- Application number: 18/312,915
- Filed: 2023-05-05
- Published: 2023-12-28
- Earliest claimed: 2016-08-12
- Assignees: Abreos Biosciences, Inc.
- Applicants: Abreos Biosciences, Inc.
- Inventors: Bradley T. MESSMER; Dina UZRI; Jessie-Farah FECTEAU
- Web page: https://patentgrep.com/patent/US20230417761A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- G01N 2333/70546: Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and assays for detecting natalizumab in a sample, natalizumab-peptide complexes in a sample, and point-of-care devices for detecting natalizumab in a sample are described herein.

## Claims

### Claim 1

A test device comprising:
(a) a sample pad for receiving a sample from a subject, wherein the sample comprises an antibody or a fragment of the antibody;
(b) a conjugate pad; and
(c) a test membrane comprising a first test line comprising a peptide consisting of any one of SEQ ID NOs: 1, 2, 4, 13, 16, and 18-23.

### Claim 2 (depends on 1)

The test device of claim 1, wherein the conjugate pad comprises a detection reagent conjugated to the peptide in step (c).

### Claim 3 (depends on 1)

The test device of claim 1, wherein the conjugate pad comprises a detection reagent conjugated to an antibody specific for natalizumab.

### Claim 4 (depends on 1)

The test device of claim 1, wherein the conjugate pad comprises a detection reagent conjugated to:
the peptide in step (c); and
an antibody specific for natalizumab.

### Claim 5 (depends on 3)

The test device of claim 3, wherein the antibody specific for natalizumab binds natalizumab at a variable region.

### Claim 6 (depends on 3)

The test device of claim 3, wherein the antibody specific for natalizumab binds natalizumab at a constant region.

### Claim 7 (depends on 1)

The test device of claim 1, wherein the test membrane further comprises a second test line comprising an antibody specific for the peptide in step (c).

### Claim 8 (depends on 7)

The test device of claim 7, wherein the antibody is natalizumab.

### Claim 9 (depends on 1)

The test device of claim 1, wherein the antibody is free, circulating natalizumab and not complexed to a protein prior to step (b).

### Claim 10 (depends on 1)

The test device of claim 1, wherein the first test line measures a bivalent form of the antibody.

### Claim 11 (depends on 7)

The test device of claim 7, wherein the second test line measures both bivalent and monovalent forms of the antibody.

### Claim 12 (depends on 1)

The test device of claim 1, wherein the test membrane comprises Western blot analysis, dot blot analysis, flow cytometry, enzyme-linked immunosorbent assay (ELISA), lateral flow immunoassay, radioimmunoassay (RIA), competitive immunoassay, dual antibody sandwich assay, chemiluminescent assay, bioluminescent assay, fluorescent assay, or agglutination assay.

### Claim 13 (depends on 1)

The test device of claim 1, wherein the first test line comprises a dual antibody sandwich assay.

### Claim 14 (depends on 7)

The test device of claim 7, wherein the second test line comprises a competitive immunoassay.

### Claim 15 (depends on 1)

The test device of claim 1, wherein the test membrane further comprises a control line.

### Claim 16 (depends on 2)

The test device of claim 2, wherein the detection reagent comprises colloidal gold.

### Claim 17 (depends on 1)

The test device of claim 1, wherein the sample is a biological fluid.

### Claim 18 (depends on 17)

The test device of claim 17, wherein the biological fluid comprises serum, plasma, whole blood, red blood cell concentrates, platelet concentrates, leukocytes concentrates, urine, cerebral spinal fluid, or sputum.

### Claim 19 (depends on 17)

The test device of claim 17, wherein the biological fluid contains antibody at a concentration of between about 0.5 mcg/mL to 120 mcg/mL.

### Claim 20 (depends on 1)

The test device of claim 1, wherein the test device is a lateral flow immunoassay (LFA) device.
